Currently, approaches combining Treg therapy for MS with IL-2 to maintain Tregs in vivo, targeted delivery to the CNS (CCR5-modified Tregs), and the use of Tregs with chimeric antigen receptors (CAR-Tregs) [104] are being tested. Here, IL2 is linked to myeloid sarcoma.